COPHF (Melodiol Global Health) Total Inventories : $0.98 Mil (As of Dec. 2023)

View and export this data going back to 2017. Start your Free Trial

What is Melodiol Global Health Total Inventories?

Melodiol Global Health's total inventories for the quarter that ended in Dec. 2023 was $0.98 Mil. Melodiol Global Health's average total inventories from the quarter that ended in Jun. 2023 to the quarter that ended in Dec. 2023 was $1.24 Mil.

In Ben Graham's calculation of Net-Net Working Capital, inventory is only considered worth half of its book value. Melodiol Global Health's Net-Net Working Capital per share for the quarter that ended in Dec. 2023 was $-1.69.

Days Inventory indicates the number of days of goods in sales that a company has in the inventory. Melodiol Global Health's Days Inventory for the six months ended in Dec. 2023 was 39.24.

Inventory Turnover measures how fast the company turns over its inventory within a year. Melodiol Global Health's Inventory Turnover for the quarter that ended in Dec. 2023 was 4.65.

Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue. Melodiol Global Health's Inventory-to-Revenue for the quarter that ended in Dec. 2023 was 0.16.

Melodiol Global Health Total Inventories Historical Data

The historical data trend for Melodiol Global Health's Total Inventories can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Melodiol Global Health Total Inventories Chart

Melodiol Global Health Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Total Inventories

Get a 7-Day Free Trial

1.67

0.94

1.33

3.90

0.98

Melodiol Global Health Semi-Annual Data
	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Total Inventories	Get a 7-Day Free Trial										1.33	1.88	3.90	1.51	0.98

Melodiol Global Health Total Inventories Calculation

Total Inventories includes the raw materials, work-in-process goods and completely finished goods of a company. It is a portion of a company's current assets.

Melodiol Global Health (OTCPK:COPHF) Total Inventories Explanation

Inventory control is an important part of business operation. If a company does not have enough inventory, it may not be able to meet customers' required delivery time. If it has too much inventory, the cost of holding the inventory can be high.

1. In Ben Graham's calculation of Net-Net Working Capital (NNWC), inventory is only considered worth half of its book value.

Melodiol Global Health's Net-Net Working Capital Per Share for the quarter that ended in Dec. 2023 is

	Net-Net Working Capital Per Share (Q: Dec. 2023 )
=	(Cash And Cash Equivalents	+	0.75 * Accounts Receivable	+	0.5 * Total Inventories	-	Total Liabilities
-	Preferred Stock	-	Minority Interest)	/	Shares Outstanding (EOP)
=	(0.463	+	0.75 * 1.602	+	0.5 * 0.978	-	15.463
-	0	-	0)	/	7.88137
=	-1.69

2. Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

Melodiol Global Health's Days Inventory for the six months ended in Dec. 2023 is calculated as:

Days Inventory	=	Average Total Inventories (Q: Dec. 2023 )	/	Cost of Goods Sold (Q: Dec. 2023 )	*	Days in Period
	=	1.2425	/	5.779	*	365 / 2
	=	39.24

3. Inventory Turnover measures how fast the company turns over its inventory within a year.

Melodiol Global Health's Inventory Turnover for the quarter that ended in Dec. 2023 is calculated as

Inventory Turnover	=	Cost of Goods Sold (Q: Dec. 2023 )	/	Average Total Inventories (Q: Dec. 2023 )
	=	5.779	/	1.2425
	=	4.65

4. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.

Melodiol Global Health's Inventory to Revenue for the quarter that ended in Dec. 2023 is calculated as

Inventory-to-Revenue	=	Average Total Inventories (Q: Dec. 2023 )	/	Revenue (Q: Dec. 2023 )
	=	1.2425	/	7.983
	=	0.16

Be Aware

Manufacturers with durable competitive advantages have the advantage that the products they sell do not change, and therefore will never become obsolete. Buffett likes this advantage.

When identifying manufacturers with durable competitive advantage, look for inventory and net earnings that rise correspondingly. This indicates that the company is finding profitable ways to increase sales which called for an increase in inventory.

Manufacturers with inventories that spike up and down are indicative of competitive industries subject to boom and bust.

Melodiol Global Health Total Inventories Related Terms

Thank you for viewing the detailed overview of Melodiol Global Health's Total Inventories provided by GuruFocus.com. Please click on the following links to see related term pages.

Melodiol Global Health Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Melodiol Global Health Ltd (OTCPK:COPHF) » Definitions » Total Inventories

Comparable Companies

Traded in Other Exchanges

1X80:Germany ME1:Australia

Address

145 Stirling Highway, Suite 5 CPC, Nedlands, WA, AUS, 6009

Website

https://www.cresopharma.com

Melodiol Global Health Ltd is engaged in developing, registering, and commercialization of pharmaceutical-grade cannabis and hemp-based nutraceutical products and treatments for human and animal health. Its brands include Mernova: A licensed producer of cannabis products in Canada for sale under the Ritual brand banner. Sierra Sage Herbs: US-based developer of plant-based, beauty, and personal care brands Green Goo, Southern Butter, and Good Goo. impACTIVE: CBD topical products for athletes. Halucenex: Clinical stage psychedelics research and development operation. Creso Pharma Switzerland: CBD-related research, development, and commercialization.

Melodiol Global Health Headlines

From GuruFocus

Halucenex Life Sciences Inc. targets Australian market following landmark TGA decision

By PRNewswire PRNewswire • 02-08-2023

Sierra Sage Herbs Acquired By Creso Pharma

By PRNewswire PRNewswire • 02-07-2022